Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer
Executive Summary
The German pharma signs collaboration to develop and commercialize larotrectinib and a follow-on, under a structure that enables Loxo to co-promote in the US and build commercial infrastructure.
You may also be interested in...
Bayer Bags Full Vitrakvi Rights As Lilly Signs Off Loxo Buy
When buying Loxo, Lilly highlighted the importance of LOXO-292, a first-in-class oral RET inhibitor, rather than the already-approved Vitrakvi, perhaps knowing that partner Bayer was going to be exercising an option to take full control of the TRK inhibitor.
Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
Lilly/Loxo Deal Came Together Quickly
Lilly's $8bn acquisition of genetics-based cancer specialist Loxo Oncology didn't involve any other bidders and was finalized in just days over the holidays as Lilly sought to make a news splash at the J.P. Morgan Healthcare conference, according to an SEC filing.